

## **PolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022**

PETACH TIKVA, Israel, April 27, 2022 — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 11, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

### **Conference Call Dial-In & Webcast Information:**

Date: Wednesday, May 11, 2022  
Time: 8:30 AM Eastern Time  
United States: +1 877-870-9135  
Israel: +972 1809 213-985  
International: +44 (0) 2071 928338  
Conference ID: 3450787  
Webcast: <https://edge.media-server.com/mmc/p/djs2mjt6>

### **About PolyPid**

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matrix) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX<sub>100</sub> is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit <http://www.polypid.com> and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

### **Contacts:**

PolyPid Ltd.  
Dikla Czaczkes Akselbrad  
EVP & CFO  
Tel: +972-747195700

### **Investors:**

Bob Yedid  
LifeSci Advisors  
646-597-6989  
Bob@LifeSciAdvisors.com

**Media:**

Nechama Feuerstein  
FINN Partners  
551-444-0784  
Nechama.Feuerstein@finnpartners.com

